Bacterium
As Drug Resistance Rises, GramEye and GSK Advance New AI-Led Infectious Disease Research
antimicrobial resistance (AMR); GramEye; GSK; AI-driven drug discovery; Gram-negative bacteria; Staphylococcus aureus; fungal infections; novel antibiotics; superbugs; infectious disease research; clinical trials
FDA withdraws two final guidances, pulls compliance deadlines for bone allograft makers
United States Food and Drug Administration, Allogeneic bone graft, Mycobacterium tuberculosis, guidances, Disease Outbreaks, standards characteristics
Vaccine-probiotic combo prevents, clears bacterial gut infections in mice in antibiotic alternative test
Antibiotics, Probiotics, House mice, Immune response, Vaccines
Sanofi and Johnson & Johnson’s E. coli Vaccine Candidate Fails in Phase 3 Trial
E. coli vaccine, Sanofi, Johnson & Johnson, Phase 3 trial failure, invasive E. coli disease, ExPEC9V
Sanofi’s E. coli Vaccine Fails Phase 3 Trial, Resulting in $250M Impairment Charge
Sanofi, Johnson & Johnson, E. coli vaccine, Phase 3 failure, impairment charge, clinical trial discontinuation
Basilea Secures $268M BARDA Funding for Antifungal and Antibacterial Development
Basilea, BARDA, antifungals, antibacterials, biotech funding, pharmaceutical development